Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Key Highlights
- ➤Avexitide reduced composite Level 2/3 hypoglycemic events 55% versus placebo
- ➤LUCIDITY met all prespecified secondary endpoints, including 63% Level 2 reduction
- ➤Amylyx targets NDA submission by year end and potential 2027 launch
- ➤Avexitide was generally well tolerated, with no treatment-related serious adverse events
Expert Statements
Camille L. Bedrosian, Chief Medical Officer at Amylyx
“The presentation of our Phase 3 LUCIDITY results represents a pivotal milestone in our work to address the longstanding treatment gap for people living with PBH. The results shared today reinforce the consistency and strength of the data, with avexitide demonstrating highly statistically significant and clinically meaningful reductions in hypoglycemic events across all prespecified endpoints”
Camille L. Bedrosian, Chief Medical Officer at Amylyx
“These positive data, together with positive results from five prior trials of avexitide in PBH, support the potential for avexitide to change practice for this debilitating condition.”
Marilyn Tan, Principal Investigator of the LUCIDITY clinical trial and Clinical Professor at the Stanford School of Medicine
“PBH is a chronic metabolic condition characterized by recurrent hypoglycemia. Each hypoglycemic event carries the potential for serious acute consequences and the cumulative burden of living with recurrent and unpredictable events can significantly affect daily functioning, independence, health and quality of life.”
Marilyn Tan, Principal Investigator of the LUCIDITY clinical trial and Clinical Professor at the Stanford School of Medicine
“The debilitating nature of this condition is clear when you look at the participants of LUCIDITY. At baseline, the majority of participants entered the study experiencing daily hypoglycemia symptoms, with many reporting a history of loss of consciousness and hypoglycemia-related hospitalizations. This substantial disease burden makes the consistent reductions in hypoglycemic events seen with avexitide compelling.”
Justin Klee, Co-CEO of Amylyx
“We're profoundly grateful to everyone who made LUCIDITY possible — from the people living with PBH who participated in our trial, to their families and care partners, as well as the investigators who share our commitment to improve outcomes for this serious condition.”
Joshua Cohen, Co-CEO of Amylyx
“We're profoundly grateful to everyone who made LUCIDITY possible — from the people living with PBH who participated in our trial, to their families and care partners, as well as the investigators who share our commitment to improve outcomes for this serious condition.”
Justin Klee, Co-CEO of Amylyx
“These results bring us meaningfully closer to what could be the first approved treatment for a community that has been waiting far too long for one. We're moving with urgency toward an NDA submission by year end and continue to prepare for a potential commercial launch of avexitide in 2027, if approved.”
Joshua Cohen, Co-CEO of Amylyx
“These results bring us meaningfully closer to what could be the first approved treatment for a community that has been waiting far too long for one. We're moving with urgency toward an NDA submission by year end and continue to prepare for a potential commercial launch of avexitide in 2027, if approved.”
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
* LUCIDITY met its prespecified primary endpoint; avexitide reduced the composite Level 2/3 hypoglycemic event rate by 55% compared to placebo (p=0.000003)
Get started
Create a free account to read the full story.
